Entecavir in Hepatitis B Virus (HBV)/HIV Co-Infected Patients

Supplement to the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents -- October 10, 2006

April 30, 2007

This article is part of The Body PRO's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.

Previously, the guidelines recommended entecavir as an option for patients who required treatment for Hepatitis B virus (HBV) but not HIV infection. This recommendation was based on in vitro data showing no significant activity of entecavir against HIV-1.1 A recent case series of three patients who received entecavir without concomitant antiretroviral therapy reported a 1 log10 decline in HIV-RNA levels and emergence of M184V mutations in one patient who was studied in detail.2

Based on these preliminary findings, the Panel recommends that:

For HBV/HIV co-infected patients, entecavir should not be used for the treatment of HBV infection without concomitant treatment for HIV.


  1. Baraclude (Product Labelling, Bristol-Myers Squibb). March 2005.
  2. McMahon M, Jilek B, Brennan T, et al. The anti-hepatitis B drug entecavir inhibits HIV-1 replication and selects HIV-1 variants resistant to antiretroviral drugs. 14th Conference on Retroviruses and Opportunistic Infections; Feb 25-28, 2007; Los Angeles, CA. Abstract 136LB.

This article was provided by AIDSinfo. Visit the AIDSinfo website to find out more about their activities and publications.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.